[338] Implementation of the Bethesda System for Reporting Thyroid Cytopathology: Observations from the 2011 Thyroid Supplemental Questionnaire of the College of American Pathologists

Manon Auger, Ritu Nayar, Walid E Khalbuss, Guliz A Barkan, Cynthia Benedict, Rosemary Tambouret, Mary R Schwartz, Lydia Howell, Rhona Souers, Andy Hartley, Nicole Thomas, Ann T Moriarty. McGill University and McGill Unversity Health Center, Montreal, PQ, Canada; Northwestern University and Northwestern Memorial Hospital, Chicago, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Loyola University and Loyola University Medical Center Bedside Test, Maywood, IL; DCL Pathology, LLC, Indianapolis, IN; Harvard University and Massachusetts General Hospital, Boston, MA; Methodist Hospital Physician Organization, Houston, TX; University of California and University of California Davis School of Medicine, Sacramento, CA; College of American Pathologists, Northfield, IL; AmeriPath Indiana, Indianapolis, IN

Background: Although information about The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has been widely disseminated since its inception in 2007, the degree of its implementation and impact on daily practice has not been formally evaluated. The objective of this study was to assess the extent of uptake of TBSRTC across pathology laboratories and to evaluate its impact on daily practice by collating participant responses to the 2011 supplemental thyroid questionnaire of the College of American Pathologists (CAP).
Design: A questionnaire was designed to gather information about various aspects of the TBSRTC and mailed in June 2011 to 2063 laboratories participating in the CAP cytopathology interlaboratory comparison program. The participating laboratories' answers were collated and analyzed.
Results: 741 laboratories returned the survey (36%). While 60.9% (N=451) and 17.1% (N=127) of laboratories reported using TBSRTC or planning to use it in the near future, respectively, 22% (N=163) had no plans to implement TBSRTC. Of the latter, 32% (N=70) stated that they were unaware of this classification. The majority (78.3%, N=343) of the laboratories use TBSRTC as published while 21.7% (N=95) use it with minor modifications. Most report that the use of TBSRTC has caused either no change (N=67, 15.2%) or only minor changes (N=353, 80.2%) in the terminology and diagnostic criteria previously used in their laboratories.
Conclusions: According to the data collected by the 2011 CAP thyroid supplemental questionnaire, TBSRTC is generally well implemented in North American pathology laboratories. However, because some participants are not aware of this new classification, further dissemination of TBSRTC is warranted.
Category: Cytopathology

Tuesday, March 5, 2013 8:00 AM

Proffered Papers: Section F, Tuesday Morning

 

Close Window